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Abstract 
Background: Hypoxic hepatitis (HH) is a frequent and potentially life-threatening event typically occurring in 
critically ill patients as a consequence of hemodynamic impairment. While acute kidney injury (AKI) has been well 
described in patients with acute liver failure, incidence and outcome of AKI accompanying HH are unclear. The aim of 
this study was to assess incidence, clinical implications and outcome of AKI and renal replacement therapy (RRT) in 
critically ill patients with HH.
Methods: A total of 1948 consecutive critically ill admissions were studied at the Medical University of Vienna. Labo-
ratory and clinical parameters as well as the presence of HH and AKI were assessed on a daily basis. Outcome, renal 
recovery and length of stay were assessed and documented, and patients were followed for 1 year.
Results: A total of 295 admissions (15 %) developed HH. Main precipitators were cardiogenic (44 %) and septic shock 
(36 %). Occurrence of HH was significantly associated with AKI [OR 4.50 (95 % CI 3.30–6.12)] and necessity of renal 
replacement therapy [RRT; OR 3.36 (95 % CI 2.58–4.37)], p < 0.001 for both. Two hundred forty admissions with HH 
(81 %) developed AKI, 159 of whom (66 %) had AKI stage 3. Both HH and AKI were significantly linked to mortality. AKI 
stage 3, international normalized ratio (INR, during HH) and the presence of septic shock were identified as independ-
ent predictors of 28-day mortality in admissions with HH, whereas RRT was identified as an independent protective 
factor. There was a synergistic effect of HH and AKI on length of stay at the ICU. Of all HH survivors treated with RRT, 
71 % showed renal recovery during follow-up.
Conclusion: HH is frequently complicated by occurrence of AKI. Severity of HH, AKI stage and the presence of septic 
shock seem to contribute to poor outcome in these patients. Initiation of RRT in HH with AKI may enable renal recov-
ery and should not be withheld in medical ICU patients.
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Background
Hypoxic hepatitis (HH) is a life-threatening complica-
tion accompanying states of oxygen depletion in critically 
ill patients at the intensive care unit (ICU) [1–5]. Inci-
dence rates of approximately 10 % have been reported in 
critically ill patients at the medical ICU [3, 4, 6, 7], and 
mortality rate in these patients was more than 50 % [1, 4, 
5]. Several risk factors for mortality in HH patients have 
been identified and include the presence of septic shock, 
sequential organ failure assessment (SOFA) score  >10, 
international normalized ratio (INR)  >2, jaundice and 
necessity of vasopressor therapy [1, 4, 5, 8].
Acute kidney injury (AKI) is a frequent complication 
in critical illness. As a consequence of various defini-
tions being used over the last decades [9], incidence rates 
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reported in the literature vary considerably ranging from 
13 to 78 % in critically ill patients [10–15].
Yet, little is known about the frequency and features 
of acute kidney injury (AKI) in HH. Interestingly, some 
recommendations on the treatment of AKI in critically 
ill patients suggest not using renal replacement therapy 
(RRT) in patients with liver failure [9]. These recom-
mendations are based on data obtained from cirrhotic 
patients with AKI and hepatorenal syndrome, respec-
tively, and are therefore not necessarily applicable to 
patients with other kinds of liver failure such as HH. In 
contrast, Kidney Disease: Improving Global Outcomes 
(KDIGO) recommendations on AKI do not make a state-
ment on patients with liver failure [16]. AKI in acute 
hepatic injury like HH may differ considerably from kid-
ney injury accompanying chronic hepatic impairment or 
acute-on-chronic liver failure. This assumption is sup-
ported by the gradual recovery of renal function in all 
patients with AKI following acetaminophen-induced 
acute liver failure [17], thereby suggesting that renal fail-
ure in acute hepatic injury and acute liver failure is fre-
quently reversible. However, to our knowledge, features 
and outcomes of AKI accompanying HH with respect to 
RRT have not been studied so far.
The aim of this study was to examine the prevalence, 
outcomes and renal recovery of AKI in patients with HH, 
the most frequent cause of severe acute hepatic impair-
ment at the ICU. Furthermore, we aimed to assess the 
role of RRT in patients with HH and AKI.
Methods
This study is based on a retrospective analysis of pro-
spectively documented data including patient long-term 
follow-up between January 2005 and December 2011. All 
patients admitted consecutively to three medical ICUs at 
the Medical University Vienna were studied. This study 
was approved by the ethics committee of the Medical 
University Vienna, which waived the need for informed 
consent due to the observational character of this study.
On admission, simplified acute physiology score II 
(SAPS II) [18], SOFA [19], infections, organ dysfunctions 
(including need for vasopressor support, mechanical ven-
tilation, RRT) and precipitating event for development of 
HH were documented. Routine laboratory analysis was 
conducted and documented on a daily basis.
All patients were screened on a daily basis for the pres-
ence of AKI defined by urine output and serum creati-
nine according to the criteria defined below [16], and 
patients were stratified according to the highest AKI 
stage observed during the ICU stay. RRT was started in 
patients with severe metabolic derangement, anuria irre-
sponsive to fluids, hyperkalemia and/or uremic complica-
tions, as previously published [20]. In patients requiring 
RRT, SOFA score was calculated daily for the first 3 days 
following initiation of RRT. Type, duration and time of 
initiation of RRT were documented. Additionally, anti-
coagulation during RRT was documented. Recovery of 
renal function was assessed during follow-up.
HH was diagnosed according to the following well-
established criteria [1, 3]: (a) a sharp but transient eleva-
tion of aminotransferase levels to at least 20-fold the 
upper limit of normal; (b) a setting of cardio-circulatory 
or respiratory failure; (c) exclusion of other potential 
causes of liver cell necrosis (viral or drug-induced hepa-
titis). If these criteria were met, a histologic confirma-
tion was not required for the diagnosis. All patients were 
screened for the presence of HH by daily laboratory and 
clinical assessment starting from ICU admission until 
ICU discharge.
Cardiogenic shock was diagnosed in patients present-
ing with (a) systolic blood pressure  <90  mmHg without 
the use of inotropes or vasopressors or requirement for 
vasopressors, (b) signs of decreased cardiac output (low 
cardiac output measured by any method, low mixed or 
central venous oxygen saturation), (c) clinical, echocardi-
ographic or radiological signs of pulmonary congestion, 
(d) absence of hypovolemia and (e) signs of organ malp-
erfusion (e.g., oliguria, cyanosis, lactate, change in men-
tal status) [21, 22]. If available, noninvasive and invasive 
measurements of hemodynamics were considered for 
diagnosis, although these methods were not a prerequi-
site for diagnosis of cardiogenic shock [23, 24].
Septic shock was defined according to the recommen-
dations of the surviving sepsis campaign [25].
Criteria for acute kidney injury were calculated accord-
ing to the KDIGO clinical practice guideline for acute 
kidney injury based on serum creatinine and urinary out-
put [16]. The value for baseline creatinine was obtained 
from the most recently measured creatinine concentra-
tion in the year prior to the ICU stay excluding the 7 days 
directly preceding ICU admission and considered to be 
representative of the baseline kidney function according 
to the judgment of the treating physician. If this baseline 
value was not available, the minimum serum creatinine 
at the time of admission to the ICU was used as baseline 
[10, 16, 26]. Renal recovery on hospital discharge was 
defined as independence from RRT [27].
ICU mortality, 28-day mortality and 1-year mortal-
ity were assessed on site or by contacting the patient or 
attending physician, respectively.
Statistical analysis
SPSS Statistics 20 (IBM, Armonk, NY, USA) was used for 
statistical analysis. Continuous variables are expressed as 
median and interquartile range (IQR 25–75  %), binary 
variables as number (%). Univariate comparisons of 
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continuous variables between groups were carried out 
using Mann–Whitney U test. Chi-square analysis and 
Fisher’s exact tests, as appropriate, were used to compare 
categorical variables. Risk factors for AKI in HH were 
assessed via ordinal logistic regression modeling.
A multivariate Cox regression model was developed in 
order to assess the impact of AKI and RRT, respectively, 
on 28-day survival in HH patients after adjustment for 
predefined confounders. Odds ratios (ORs) and hazard 
ratios (HRs) are presented with 95 % confidence intervals 




A total of 1948 admissions were studied at three medi-
cal ICUs. Two hundred ninety-five admissions developed 
HH (15 %) during their stay at the ICU. In the vast major-
ity (n = 229, 78 %), HH occurred within 24 h from ICU 
admission; 253 (86 %) developed HH within 48 h. Median 
time from ICU admission to occurrence of HH was 0 
(IQR 0–1) days. Main precipitants for occurrence of HH 
were cardiogenic shock (n  =  130; 44  %), septic shock 
(n  =  106; 36  %), hemorrhagic shock (n  =  8; 3  %) and 
mixed cardiogenic/septic shock (n = 3; 1 %). A detailed 
list of underlying conditions associated with occurrence 
of HH is shown in Additional file 1: Table S1. Two hun-
dred forty-two admissions (12  %) had underlying liver 
cirrhosis. Clinical and laboratory features of 295 admis-
sions with HH are illustrated in Table 1.
Acute kidney injury and renal replacement therapy
Of all 1948 admissions studied during the observation 
period, 55  % (1054 admissions) developed AKI within 
48 h after ICU admission. AKI stages 1, 2 and 3 occurred 
in 128 (7 %), 345 (18 %) and 581 (30 %) admissions to the 
ICU, respectively. Of those admissions with AKI stage 
3, 70 % (n = 409) received RRT for a median of 4 (2–10) 
days. In total, 409 admissions (21 %) underwent RRT dur-
ing their ICU stay with the median time from admission 
to initiation of RRT being 1 (IQR 0–3) day. A list of under-
lying reasons for initiation of RRT stratified according to 
the presence of HH is shown in Additional file 1: Table S2.
The distribution of AKI stages in admissions with and 
without HH is illustrated in Fig. 1. HH was significantly 
associated with AKI and RRT in the univariate analy-
sis [OR 4.50 (95  % CI 3.30–6.12)] and [OR 3.36 (95  % 
CI 2.58–4.37); p  <  0.0001 for both]. Two hundred forty 
admissions with HH (81 %) developed AKI, 159 of whom 
(66  %) had AKI stage 3. Risk factors for occurrence of 
AKI in HH are illustrated in Table 2.
In admissions who developed HH, the percent-
age receiving RRT was significantly higher compared 
to critically ill admissions without HH (41  vs. 17  %, 
p  <  0.001). This relationship is illustrated in a Cox-
adjusted hazard plot (Additional file  2: Figure  S1; 
adjusted for age, sex and SOFA score). Of all admissions 
with HH receiving renal support, 96 (79 %) had continu-
ous RRT, 11 (9  %) underwent intermittent RRT, and 15 
(12  %) had both continuous and intermittent types of 
RRT during their stay at the ICU.
Heparin (n = 80, 66 %) and citrate (n = 26, 21 %) were 
the most frequently used substances for anticoagula-
tion. Epoprostenol and danaparoid were used in 5 (4 %) 
patients and 1 (1  %) patient, respectively. In 10 (8  %) 
Table 1 Characteristics of  295 admissions with  hypoxic 
hepatitis
SAPS II simplified acute physiology score, SOFA sequential organ failure 
assessment, MAP mean arterial pressure, AST aspartate aminotransferase, ALT 
alanine aminotransferase, LDH lactate dehydrogenase, ICU-LOS length of stay at 
the ICU, IQR interquartile range
Parameter
Number of patients 295
Admission parameters
 Age (years), median (IQR) 63 (51–72)
 Females, n (%) 94 (32 %)
 SAPS II, median (IQR) 62 (45–79)
 SOFA, median (IQR) 11 (8–15)
 Heart rate (bpm), median (IQR) 81 (65–104)
 MAP (mmHg), median (IQR) 68 (57–82)
 Respiratory rate (breaths/min), median (IQR) 20 (16–25)
 Body temperature (°C), median (IQR) 36.5 (35.5–37.5)
 pH, median (IQR) 7.30 (7.20–7.40)
 AST (IU/l), median (IQR) 366 (73–1265)
 ALT (IU/l), median (IQR) 139 (39–706)
 LDH (IU/l), median (IQR) 599 (360–1523)
 INR, median (IQR) 1.4 (1.2–1.9)
Peak values
 AST (IU/l), median (IQR) 2457 (1168–5605)
 ALT (IU/l), median (IQR) 1151 (534–2620)
 LDH (IU/l), median (IQR) 2439 (1334–4999)
 INR, median (IQR) 1.8 (1.4–2.7)
Underlying condition
 Cardiogenic shock, n (%) 130 (44 %)
 Septic shock, n (%) 106 (36 %)
 Mixed septic/cardiogenic shock, n (%) 3 (1 %)
 Hemorrhagic shock, n (%) 8 (3 %)
Therapy
 Mechanical ventilation, n (%) 225 (76 %)
 Vasopressor therapy, n (%) 231 (86 %)
 Renal replacement therapy, n (%) 122 (41 %)
Outcome parameters
 28-day mortality, n (%) 170 (58 %)
 ICU-LOS (days), median (IQR) 7 (2–14)
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admissions, the substance used for anticoagulation with 
RRT was changed during the stay at the ICU.
Mortality in HH accompanied by AKI
Both HH and AKI were significantly linked to mortal-
ity as illustrated in Cox-adjusted survival curves (Fig. 2, 
adjusted for age, sex and SOFA score). The worst out-
comes, though, were observed in patients with the pres-
ence of HH and AKI (28-day mortality 64 %).
AKI stage 3, peak INR (within 48 h after occurrence of 
HH) and the presence of septic shock were identified as 
independent predictors of 28-day mortality in admissions 
with HH by multivariate Cox regression (Table 3). After 
adjustment for these factors, RRT was identified as an 
independent protective factor regarding 28-day mortality 
(Table 3).
In HH patients requiring RRT, SOFA scores and num-
ber of organs failing during the first 3 days of RRT were 
associated with 28-day mortality (Additional file  1: 
Table  S3). Persisting failure of  ≥5 organs and/or SOFA 
scores above 20 for more than 48 h despite initiation of 
RRT was associated with a 100 % mortality rate.
Time from onset of AKI to initiation of RRT did not 
differ significantly between 28-day survivors and non-
survivors [2 (0–7) days vs. 1 (0–3) days, p = 0.164]. No 
difference in 28-day mortality was observed between 
the two most frequently used methods of anticoagula-
tion [heparin (n =  64, 80  %) vs. citrate (n =  19, 73  %); 
p = 0.457]. Similarly, incidence of bleeding complications 
did not differ between HH patients with heparin and 
citrate anticoagulation [n =  11 (14 %) vs. n =  3 (12 %), 
p = 0.772].
In the vast majority (n  =  218, 91  %) of HH patients 
with AKI, AKI occurred within 48 h prior to or after HH. 
RRT was initiated after occurrence of HH in 54 patients 
(44 %), on the same day of HH in 32 patients (26 %), prior 
to HH in 36 patients (30 %).
Length of stay at the ICU in HH and AKI
Overall length of stay (LOS) at the ICU did not differ sig-
nificantly between HH admissions with and without AKI 
[6 (IQR 2–13) days vs. 8 (IQR 3–14) days; p  =  0.295], 
which was attributable to the high mortality rate in AKI 
accompanying HH. However, in ICU survivors, HH and 
AKI significantly affected ICU-LOS (Additional file  3: 
Figure  S2). Median LOS in ICU survivors was 3 (2–8) 
days in admissions without HH or AKI, 9 (4–14) days 
HH without AKI, 5 (2–12) days in AKI without HH and 8 
(5–20) days in admissions with both HH and AKI. Addi-
tionally, compared to admissions without HH and RRT, 
respectively, ICU-LOS more than doubled when HH was 
accompanied by need for RRT [4 (IQR 2–10) days vs. 10 
(IQR 3–20) days], p < 0.0001.
Renal recovery and long‑term outcomes
Twenty-four admissions with HH and RRT survived their 
stay at the ICU. The ICU survival rate was significantly 
lower compared to admissions with RRT but without HH 
(20 % in patients with HH compared to 64 % in non-HH 
admissions, p  <  0.001). Seventeen out of the 24 admis-
sions (71  %) showed recovery of renal function at the 
time of hospital discharge. There was a trend for lower 
1-year mortality in HH admissions with RRT and recov-
ery of renal function compared to those without renal 
recovery [4 (24 %) vs. 4 (57 %), p = 0.167].
In admissions requiring RRT who survived the ICU 
stay (n = 207, 51 %), 1-year mortality rate did not differ 
significantly between those who had and who had not 
experienced HH [8 (33 %) vs. 68 (37 %), p = 0.715].
Discussion
This is the first study that assesses features and outcomes 
of AKI and RRT in patients with HH compared to a large 
control group of critically ill patients. Our results demon-
strate that HH is frequently accompanied by AKI. Most 
of the HH patients developed AKI stage 3. Importantly, 
occurrence of AKI was associated with increased mortal-
ity and length of stay in patients with HH.
Our study demonstrates that AKI is a frequent com-
plication in critically ill patients associated with poor 
outcome [10–14]. In our total cohort, incidence rate of 
Fig. 1 Distribution of AKI stages (KDIGO) in patients with and with-
out hypoxic hepatitis. HH hypoxic hepatitis, AKI acute kidney injury—
stratified according to the KDIGO criteria [16]
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AKI was 55 % (and 49 % even in patients without HH), 
thus considerably higher than recently reported in the 
FINNAKI study (39 % incidence of AKI) [10]. However, 
incidence of AKI in our total cohort is comparable to 
recently published incidence rates according to KDIGO 
criteria in critically ill patients [26].
AKI was observed in the vast majority of HH patients 
with only 19 % preserving normal renal function. There 
was a temporal relationship between HH and AKI, and 
in most affected patients both events occurred early dur-
ing the ICU stay. However, the temporal relationship 
varied between patients. AKI in HH was associated with 
severity of illness reflected by SAPS and SOFA score, but 
most importantly with shock, vasopressor use and admis-
sion lactate levels. Thus, ischemia and tissue hypoxia 
seem to play a crucial role in development of AKI in HH.
In accordance with other studies [10, 17], ICU stay was 
significantly prolonged in patients with AKI; 28-day mor-
tality rate in patients with AKI was 40 % in the total study 
cohort. In contrast, AKI in HH was associated with sig-
nificantly higher 28-day mortality rates exceeding 60  % 
by far. The high mortality rates are in part attributable to 
the severity of illness reflected by high SAPS and SOFA 
scores on ICU admission. Yet, AKI, the presence of septic 
Table 2 Univariate ordinal logistic regression model linking demographic, physiological and  laboratory parameters 
to AKI in HH
SAPS II simplified acute physiology score, SOFA sequential organ failure assessment, HH hypoxic hepatitis, MCI myocardial infarction, RRT renal replacement therapy, 
AST aspartate aminotransferase, ALT alanine aminotransferase, INR international normalized ratio, IQR interquartile range
* p values calculated using univariate ordinal logistic regression modeling with intercept
a Three patients had both cardiogenic and septic shock (mixed shock)
Parameter Overall AKI Stage p value*
n = 295 0 (n = 55) 1 (n = 23) 2 (n = 56) 3 (n = 161)
Baseline characteristics
 Age, years (IQR) 63 (51–72) 60 (45–71) 62 (50–77) 65 (54–71) 63 (52–71) 0.325
 Sex (male), n (%) 201 (68 %) 31 (56 %) 19 (83 %) 35 (63 %) 116 (72 %) 0.086
 SAPS II (IQR) 62 (45–79) 50 (33–68) 52 (37–73) 59 (38–75) 70 (52–86) <0.001
 SOFA (IQR) 11 (8–15) 10 (7–12) 9 (7–12) 10(6–13) 12 (8–16) <0.001
 Respiratory rate, bpm (IQR) 20 (16–25) 18 (15–22) 18 (15–27) 20 (16–25) 21 (17–27) 0.080
 Body temperature, C° (IQR) 36.0 (34.8–36.8) 35.5 (33.6–36.5) 35.6 (33.5–36.5) 36.4 (35.2–36.9) 36.1 (35.0–36.8) 0.893
 Heart rate, bpm (IQR) 81 (65–104) 79 (61–95) 83 (60–107) 79 (60–98) 83 (66–108) 0.119
 Mean arterial pressure, mmHg (IQR) 68 (57–79) 73 (63–83) 72 (58–80) 70 (61–83) 65 (54–76) <0.01
 Preexisting liver cirrhosis, n (%) 22 (7 %) 1 (2 %) 0 5 (9 %) 16 (10 %) <0.05
Cause of HH
 Cardiogenic shock, n (%)a 133 (45 %) 27 (49 %) 15 (65 %) 28 (50 %) 63 (39 %) <0.05
 Septic shock, n (%)a 109 (37 %) 12 (22 %) 5 (22 %) 14 (25 %) 78 (48 %) <0.001
 Hemorrhagic shock, n (%) 8 (3 %) 0 0 1 (2 %) 7 (4 %) 0.081
Therapy
 Mechanical ventilation, n (%) 225 (76 %) 36 (66 %) 19 (83 %) 35 (63 %) 135 (84 %) <0.01
 Vasopressor use, n (%) 247 (84 %) 38 (69 %) 18 (78 %) 35 (80 %) 146 (91 %) <0.001
RRT, n (%) 122 (41 %) 0 0 0 122 (76 %) <0.001
Laboratory parameters on admission
 Arterial lactate, mmol/l (IQR) 3.5 (1.7–8.2) 2.0 (1.2–4.4) 2.7 (1.6–5.7) 3.5 (2.1–6.9) 4.3 (2.1–10.6) <0.001
 Arterial pH (IQR) 7.30 (7.20–7.40) 7.39 (7.30–7.47) 7.32 (7.28–7.39) 7.32 (7.24–7.41) 7.27 (7.15–7.36) <0.001
 Sodium, mmol/l (IQR) 138 (133–142) 138 (133–140) 140 (136–143) 138 (133–141) 138 (133–142) 0.387
 Potassium, mmol/l (IQR) 4.5 (3.9–5.2) 4.1 (3.6–4.7) 4.0 (3.7–4.4) 4.5 (4.1–5.1) 4.7 (4.1–5.5) 0.906
 Albumin, g/l (IQR) 29.3 (24.1–34.0) 29 (24–32) 30 (26–36) 30 (24–35) 29 (24–34) 0.405
 AST, U/l (IQR) 366 (73–1265) 345 (77–781) 474 (85–1341) 699 (108–1599) 248 (57–1475) 0.142
 ALT, U/l (IQR) 139 (39–706) 129 (55–639) 219 (54–631) 217 (44–1470) 124 (34–682) 0.731
 INR (IQR) 1.4 (1.2–1.9) 1.3 (1.1–1.6) 1.3 (1.1–1.4) 1.4 (1.2–1.9) 1.5 (1.2–2.1) 0.142
 Bilirubin, mg/dl (IQR) 1.3 (0.7–2.7) 1.0 (0.6–2.1) 0.9 (0.7–1.6) 1.3 (0.8–3.1) 1.4 (0.7–3.2) <0.05
Outcome
 28-day mortality, n (%) 170 (58 %) 17 (31 %) 6 (26 %) 25 (45 %) 122 (76 %) <0.001
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shock and peak INR values during HH were independent 
predictors of mortality in HH patients. Furthermore, we 
observed a synergistic effect of HH and AKI resulting in 
longer stay and increased mortality at the ICU. One reason 
for that observation may be the described systemic effects 
of AKI, which may further impair liver function [28].
Initiation of RRT was identified as an independent 
protective factor regarding survival in patients with HH. 
While necessity of RRT was significantly associated with 
increased 28-day mortality in the univariate analysis, 
this effect was completely abolished after adjustment for 
demographics, AKI, septic shock, INR and severity of dis-
ease. Initiation of RRT may provide beneficial effects in 
patients with HH. Apart from regulation of fluid balance, 
metabolic stabilization and removal of water-soluble 
toxins may contribute to this hypothesis. Best timing for 
initiation of RRT in critically ill patients is still a matter of 
debate. A recent large randomized controlled study com-
paring early versus late initiation of RRT in critically ill 
patients could not observe a difference in outcome [29]. 
Yet, future studies are required to assess timing, modality 
and potential benefits of RRT in patients with HH com-
plicated by AKI.
Renal recovery was observed in the majority (71 %) of 
ICU survivors with HH and necessity of RRT. This find-
ing is comparable to patients with ALF, where similarly 
high rates of renal recovery in patients requiring RRT 
have been described [30].
On the other hand, we observed a 100 % mortality rate 
in admissions with persisting failure of  ≥5 organs (or 
Fig. 2 Cox-adjusted survival curves illustrating the impact of HH and AKI on survival in critically ill patients. HH hypoxic hepatitis, AKI acute kidney 
injury, ICU intensive care unit; adjusted for age, sex, sequential organ failure assessment (SOFA) score; significant differences between patients with 
HH and/or AKI compared to patients without HH or AKI (p < 0.05); adjusted hazard ratio (HR) for 28-day mortality in patients with HH and AKI was 
4.26 (95 % CI 3.30–5.51), p < 0.001
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SOFA scores >20) despite use of RRT for at least 2 days. 
Thus, our data suggest that continuation of RRT and 
other therapeutic measures should be repeatedly reeval-
uated on an individual basis in critically ill HH patients 
who present with persisting 5- or 6-organ failure despite 
use of RRT for more than 48 h. Furthermore, future stud-
ies are needed to address the question of when to start 
and to stop RRT in patients with (persisting) multi-organ 
failure.
Consensus recommendations on prevention and man-
agement of AKI in critically ill patients suggest that RRT 
should not be used in patients with liver failure, who are 
not candidates for liver transplantation [9]. Yet, the char-
acteristic laboratory pattern of HH presenting with high 
aminotransferase levels and increased INR frequently 
fulfills criteria of acute liver failure [2, 7, 31]. Thus, dis-
tinguishing HH from other types of acute liver injury is 
of crucial importance due to its different clinical pattern 
and therapeutic consequences. It has been suggested 
that “the ability to manage heart failure or other causes 
of ischemia successfully will determine outcome for these 
(HH) patients, and transplantation is seldom indicated” 
[31]. Given the high incidence rates of HH in critically 
ill patients [2, 4, 6], HH should be considered as one of 
the primary differential diagnoses in patients with mas-
sive elevation of aminotransferase levels in the setting of 
critical illness. Our data suggest that, although mortality 
is still very high, RRT should be initiated in patients with 
HH developing AKI. Thus, RRT should not be withheld 
in patients with unclear elevation of aminotransferase 
levels at the ICU until the etiology has been clarified.
This study has strengths and limitations. This study 
comprises one of the largest datasets on HH published so 
far and uncovered for the first time the previously unrec-
ognized association with AKI. Furthermore, the control 
group (without HH) contains 1653 critically ill medical 
patients. This sample size enables a good characterization 
of AKI in HH as compared to AKI in patients without 
HH. Yet, this study was conducted at three medical ICUs. 
Thus, our data may not be transferable to surgical ICUs 
or wards. Residual confounding arising from unmeasured 
covariates cannot be entirely excluded. Thus, further 
studies in different samples are required.
Conclusions
In sum, we could demonstrate that AKI frequently 
occurs in HH and is associated with high mortality and 
increased length of stay in survivors. Severity of the 
underlying disease and states of shock seem to contribute 
to AKI and poor outcome in HH. Initiation of RRT in HH 
with AKI may enable renal recovery and should not be 
withheld in medical ICU patients.
Table 3 Cox regression model for 28-day mortality in HH
SOFA sequential organ failure assessment, INR international normalized ratio, AKI acute kidney injury
* p<0.05, ** p<0.01
a Patients with chronic liver disease included—adjusted for all variables (total n= 295 )
b Patients with chronic liver disease excluded—adjusted for all variables (total n = 273)
Parameter Hazard ratio (95% CI)
Unadjusted Adjusteda Adjustedb
Age 1.01 (0.99–1.02) 1.01 (0.99–1.02) 1.00 (0.99–1.02)
Gender (male) 1.22 (0.87–1.70) 1.18 (0.83–1.67) 1.26 (0.86–1.84)
Admission SOFA score 1.08 (1.04–1.12)** 1.04 (0.99–1.07) 1.03 (0.99–1.07)
Septic shock 2.07 (1.53–2.80)** 2.15 (1.32–3.50)** 2.37 (1.41–
3.97)**
Cardiogenic shock 0.86 (0.64–1.17) 1.62 (0.99–2.63) 1.94 (1.16–3.24)*
INR 1.29 (1.20–1.39)** 1.24 (1.14–1.34)** 1.26 (1.13–
1.39)**
Acute kidney injury (AKI)
 AKI 1 vs. no AKI 0.83 (0.33–2.11) 0.77 (0.30–1.95) 0.78 (0.30–2.00)
 AKI 2 vs. no AKI 1.69 (0.91–3.12) 1.50 (0.81–2.79) 1.55 (0.81–2.97)
 AKI 3 vs. no AKI 3.48 (2.09–5.78)** 3.40 (1.85–6.24)** 3.51 (1.86–
6.62)**
Renal replacement therapy 1.86 (1.37–2.51)** 0.64 (0.42–0.97)* 0.62 (0.39–0.97)*
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